S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:AKRO

Akero Therapeutics (AKRO) Stock Forecast, Price & News

$8.97
-0.01 (-0.11%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.78
$9.32
50-Day Range
$8.74
$15.60
52-Week Range
$8.50
$30.53
Volume
406,194 shs
Average Volume
297,026 shs
Market Capitalization
$314.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.77
30 days | 90 days | 365 days | Advanced Chart
Receive AKRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akero Therapeutics logo

About Akero Therapeutics

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
33
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.18 per share

Profitability

Net Income
$-100.78 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,540,000
Market Cap
$314.13 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/06/2022
Today
5/21/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

596th out of 1,416 stocks

Pharmaceutical Preparations Industry

268th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Akero Therapeutics (NASDAQ:AKRO) Frequently Asked Questions

Is Akero Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Akero Therapeutics stock.
View analyst ratings for Akero Therapeutics
or view top-rated stocks.

When is Akero Therapeutics' next earnings date?

Akero Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Akero Therapeutics
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its quarterly earnings data on Friday, May, 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.06.
View Akero Therapeutics' earnings history
.

What price target have analysts set for AKRO?

3 analysts have issued twelve-month price targets for Akero Therapeutics' stock. Their forecasts range from $29.00 to $62.00. On average, they expect Akero Therapeutics' stock price to reach $43.67 in the next year. This suggests a possible upside of 386.8% from the stock's current price.
View analysts' price targets for Akero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akero Therapeutics' key executives?
Akero Therapeutics' management team includes the following people:
  • Dr. Andrew Cheng M.D., Ph.D., Pres, CEO & Director (Age 55, Pay $849.06k)
  • Dr. Jonathan M. Young, Co-Founder, Exec. VP, COO & Sec. (Age 52, Pay $621k) (LinkedIn Profile)
  • Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer (Age 68, Pay $621k)
  • Mr. William R. White J.D., Exec. VP, CFO, Treasurer & Head of Corp. Devel. (Age 49, Pay $614.15k)
  • Ms. Catriona Yale, Exec. VP & Chief Devel. Officer (Age 49) (LinkedIn Profile)
  • Mr. John J. Schembri, VP of Fin. & Controller (Age 60)
What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), (NGM) and VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (6.37%), BlackRock Inc. (5.41%), State Street Corp (3.54%), Vanguard Group Inc. (3.50%), Goldman Sachs Group Inc. (3.12%) and Rock Springs Capital Management LP (1.81%). Company insiders that own Akero Therapeutics stock include Andrew Cheng, Apple Tree Partners Iv, LP, Catriona Yale, Global Strategic Fund I Venbio, Jonathan Young, Kevin Bitterman and William Richard White.
View institutional ownership trends for Akero Therapeutics
.

Which institutional investors are selling Akero Therapeutics stock?

AKRO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Citigroup Inc., Simplex Trading LLC, Northern Trust Corp, Jane Street Group LLC, Metropolitan Life Insurance Co NY, and Royal Bank of Canada. Company insiders that have sold Akero Therapeutics company stock in the last year include Andrew Cheng, Catriona Yale, Jonathan Young, Kevin Bitterman, and William Richard White.
View insider buying and selling activity for Akero Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Akero Therapeutics stock?

AKRO stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Integral Health Asset Management LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., Renaissance Technologies LLC, Rock Springs Capital Management LP, and UBS Group AG.
View insider buying and selling activity for Akero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akero Therapeutics?

Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $8.97.

How much money does Akero Therapeutics make?

Akero Therapeutics has a market capitalization of $314.13 million. The company earns $-100.78 million in net income (profit) each year or ($3.200010) on an earnings per share basis.

How many employees does Akero Therapeutics have?

Akero Therapeutics employs 33 workers across the globe.

What is Akero Therapeutics' official website?

The official website for Akero Therapeutics is www.akerotx.com.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 487-6488 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.